ArticleCase reports in pulmonology2025
A Subtle Presentation of Pharyngitis and Pneumonia: Lemierre Syndrome.
Article in Case reports in pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lemierre syndrome (LS) is a rare condition with an estimated incidence of 1-10/1,000,000 per year defined as a complication of an oral and nasopharyngeal infection with secondary septicemia leading to septic emboli and internal jugular vein thrombosis. This syndrome was first described by Andre' Lemierre in 1936, before the development of antibiotics. In the preantibiotic era, it was a common condition and it was often characterized by a fatal course within 7-15 days with a mortality rate that could reach up to 80% of cases. After the development of antibiotic therapies, the incidence of LS rapidly declined, and nowadays, it is also known as "the forgotten disease," but the mortality risk remains high (5%) especially in case of diagnostic delay and inappropriate therapies. We presented a case of a 23-year-old who was referred to our hospital for worsening dyspnea associated with high fever following a pharyngitis in order to raise awareness about this severe rare disease. Long-term outcomes are usually good if proper treatment is started with no delay. The mainstays of treatment for the pulmonary and vascular aspects are antibiotic treatment with or without anticoagulation and chest-tube drainage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.